Ramiro Guerrero Acquires 8,931 Shares of MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero bought 8,931 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were bought at an average price of $1.39 per share, for a total transaction of $12,414.09. Following the completion of the transaction, the director directly owned 610,842 shares of the company’s stock, valued at $849,070.38. This represents a 1.48% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Ramiro Guerrero also recently made the following trade(s):

• On Friday, August 28th, Ramiro Guerrero purchased 46,620 shares of MAIA Biotechnology stock. The stock was bought at an average price of $1.35 per share, with a total value of $62,937.00.
• On Thursday, August 27th, Ramiro Guerrero acquired 78,239 shares of MAIA Biotechnology stock. The shares were bought at an average cost of $1.39 per share, for a total transaction of $108,752.21.
• On Monday, August 24th, Ramiro Guerrero acquired 1,794 shares of MAIA Biotechnology stock. The shares were bought at an average price of $1.33 per share, with a total value of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero bought 11,899 shares of MAIA Biotechnology stock. The shares were purchased at an average price of $1.37 per share, for a total transaction of $16,301.63.

MAIA Biotechnology Price Performance

Shares of NYSEAMERICAN:MAIA opened at $1.37 on Thursday. The company has a market capitalization of $83.34 million, a P/E ratio of -2.21 and a beta of 0.25. MAIA Biotechnology, Inc. has a 1-year low of $0.87 and a 1-year high of $3.19. The firm’s 50 day simple moving average is $1.37 and its two-hundred day simple moving average is $1.43.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, sell-side analysts anticipate that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MAIA Biotechnology

A number of institutional investors have recently bought and sold shares of the business. Marshall Wace LLP bought a new stake in MAIA Biotechnology during the second quarter valued at about $29,000. PVG Asset Management Corp bought a new position in shares of MAIA Biotechnology in the first quarter worth about $46,000. Susquehanna International Group LLP bought a new position in shares of MAIA Biotechnology in the second quarter worth about $51,000. Jane Street Group LLC purchased a new stake in shares of MAIA Biotechnology during the second quarter worth about $52,000. Finally, Corsair Capital Management L.P. purchased a new stake in shares of MAIA Biotechnology during the first quarter worth about $140,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.